All Officials
Select methods...
Lobbying Records (Page 1 of 2)
2025-09-17
Politician(s) lobbied: Billy Kelleher (MEP), European Parliament
Intent: Secure meeting with MEP Kelleher to discuss EU General Pharma Legislation, Critical Medicines Act, and the upcoming Biotech Act
Methods: Email
Details & Methods:
| Method | Description |
|---|---|
| — | Requested a meeting with MEP Kelleher to introduce Amgen and discuss EU General Pharma Legislation |
| — | Critical Medicines Act |
| — | and the upcoming Biotech Act |
2025-09-17
Politician(s) lobbied: Laura Mannion (Special Advisor), Department of Enterprise, Trade and Employment; Peter Burke (Minister), Department of Enterprise, Trade and Employment
Intent: Provide education on Critical Medicines Act and other biopharma industry topics
Methods: Meeting
Details & Methods:
| Method | Description |
|---|---|
| — | Discussion of Critical Medicines Act and other biopharma industry topics |
2025-05-20
Politician(s) lobbied: Micheál Martin (Taoiseach), Dáil Éireann, the Oireachtas
Intent: Share with an Taoiseach our views on trade policy and impact on the pharmaceuticals sector
Methods: Phone call
Details & Methods:
| Method | Description |
|---|---|
| — | Conversation on trade policy and the impact on the pharmaceuticals sector |
2025-05-20
Politician(s) lobbied: Billy Kelleher (MEP), European Parliament
Intent: Secure meeting with MEP Billy Kelleher to discuss EU legislation
Methods: Email
Details & Methods:
| Method | Description |
|---|---|
| — | Email requesting a meeting with MEP Billy Kelleher to discuss EU legislation such as the Critical Medicines Act and upcoming Biotech Act |
2025-05-20
Politician(s) lobbied: Cynthia Ní Mhurchú (MEP), European Parliament
Intent: Share information with MEP Cynthia NÍ MHURCHÚ on EU legislation
Methods: Meeting
Details & Methods:
| Method | Description |
|---|---|
| — | Meeting with MEP Cynthia NÍ MHURCHÚ on EU legislation such as the Critical Medicines Act and upcoming Biotech Act |
2025-01-17
Politician(s) lobbied: Peter Burke (Minister), Department of Enterprise, Trade and Employment; Pauline Mulligan (Assistant Secretary), Department of Enterprise, Trade and Employment
Intent: To discuss with Minister Burke Amgen's current and future investments in Ireland and emerging public policy issues of interest
Methods: Meeting
Details & Methods:
| Method | Description |
|---|---|
| — | Discussed Amgen's current and future investments in Ireland; discussed EU Pharma Legislation. |
2025-01-17
Politician(s) lobbied: Peter Burke (Minister), Department of Enterprise, Trade and Employment
Intent: Meet with Minister Burke to discuss EU pharmaceutical legislation, market access to innovative medicines, and Amgen's manufacturing footprint
Methods: Meeting
Details & Methods:
| Method | Description |
|---|---|
| — | Discussed EU pharmaceutical legislation |
| — | market access to innovative medicines |
| — | and Amgen's manufacturing footprint in Ireland |
2025-01-17
Politician(s) lobbied: Simon Harris (An Taoiseach), Department of the Taoiseach; Max Murphy (Special Adviser), Department of the Taoiseach
Intent: Meet with the Taoiseach to discuss EU pharmaceutical legislation, IP, market access to innovative medicines, and Amgen's manufacturing footprint in Ireland
Methods: Meeting
Details & Methods:
| Method | Description |
|---|---|
| — | Discussed EU pharmaceutical legislation |
| — | IP |
| — | market access to innovative medicines |
| — | and Amgen's manufacturing footprint in Ireland |
2025-01-17
Politician(s) lobbied: Billy Kelleher (MEP), European Parliament
Intent: Participate in hosted roundtable event
Methods: Event / Reception
Details & Methods:
| Method | Description |
|---|---|
| — | Discussed EU competitiveness for biopharmaceutical industry investments at ALDE 2024 party conference roundtable; discussed Biotech Act |
| — | EU Pharma Legislation |
| — | and Draghi Report. |
2025-01-17
Politician(s) lobbied: Seán Kelly (MEP), European Parliament
Intent: Discussion on importance of improving EU competitiveness
Methods: Meeting
Details & Methods:
| Method | Description |
|---|---|
| — | Discussed regulation |
| — | need to keep EU competitive and support more clinical trials in Europe as part of AmCham EU delgation |